MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

20.45 -0.29

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

20.22

Máximo

20.56

Métricas clave
By Trading Economics
Ingresos	-4.6M 52M
Ventas	5.1M 147M
P/B Media del Sector	12.364 36.442
Margen de beneficios	35.553
Empleados	181
EBITDA	5.9M 79M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+60.74% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-154M 2.5B
Apertura anterior	20.74
Cierre anterior	20.45

Noticias sobre sentimiento de mercado

By Acuity

50%

159 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 oct 2025, 18:13 UTC

Principales Movimientos del Mercado

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 oct 2025, 17:05 UTC

Principales Movimientos del Mercado

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

17 oct 2025, 15:03 UTC

Principales Movimientos del Mercado

Obook Shares Sink Following Public Debut

17 oct 2025, 14:41 UTC

Principales Movimientos del Mercado

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

17 oct 2025, 23:25 UTC

Adquisiciones, fusiones, absorciones

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct 2025, 22:15 UTC

Charlas de Mercado

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct 2025, 21:15 UTC

Charlas de Mercado

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 oct 2025, 21:07 UTC

Charlas de Mercado

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 oct 2025, 21:07 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 oct 2025, 20:34 UTC

Charlas de Mercado

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 oct 2025, 20:27 UTC

Charlas de Mercado

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 oct 2025, 19:46 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 oct 2025, 19:45 UTC

Charlas de Mercado

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 oct 2025, 18:45 UTC

Charlas de Mercado

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 oct 2025, 17:51 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 oct 2025, 17:51 UTC

Charlas de Mercado

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 oct 2025, 17:44 UTC

Charlas de Mercado

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 oct 2025, 17:35 UTC

Charlas de Mercado

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 oct 2025, 16:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

17 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 oct 2025, 16:14 UTC

Charlas de Mercado

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 oct 2025, 16:04 UTC

Charlas de Mercado

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 oct 2025, 15:58 UTC

Charlas de Mercado

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 oct 2025, 15:56 UTC

Ganancias

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 oct 2025, 15:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 oct 2025, 15:43 UTC

Charlas de Mercado

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

17 oct 2025, 14:58 UTC

Charlas de Mercado

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

17 oct 2025, 14:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 oct 2025, 14:35 UTC

Charlas de Mercado

Ganancias

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

60.74% repunte

Estimación a 12 Meses

Media 33 USD 60.74%

Máximo 35 USD

Mínimo 31 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

159 / 371 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.